Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome

American Journal of Hematology

Volumn 73, Issue 4, 2003, Pages 249-255

  Le Coutre, Philipp ^c   Kreuzer, Karl Anton ^c   Na, Il Kang ^c   Schwarz, Michaela ^c   Lupberger, Joachim ^c   Holdhoff, Matthias ^c   Baskaynak, Gökben ^c   Gschaidmeier, Harald ^a   Platzbecker, Uwe ^b   Ehninger, Gerhard ^b   Prejzner, Witold ^c   Huhn, Dieter ^c   Schmidt, Christian A ^c  

^a Novartis Pharma AG   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN; IMATINIB; OROSOMUCOID;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ECZEMA; EDEMA; EPISTAXIS; FEMALE; HEMATOMA; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOPENIA; MALE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; OBESITY; PETECHIA; PHILADELPHIA 1 CHROMOSOME; PREDICTION; PRIORITY JOURNAL; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VERTIGO; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CYTOGENETIC ANALYSIS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; OROSOMUCOID; PIPERAZINES; PROGNOSIS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; RNA, MESSENGER; TIME FACTORS;

EID: 10744230746     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10364     Document Type: Article

References (18)

1. Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL-positive cells. Nat Med 1996;2:561-566.
3. + leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-394.
4. Deininger MW, Goldmann JM, Lydon N, Melo J. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
5. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR-ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999;91:163-168.
6. Druker BJ, Talpaz M, Resta DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
7. Druker BJ, Sawyers CL, Kantarjian H. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
8. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293(5531):876-880.
9. le Coutre P, Tassi E, Varella-Garcia M, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 2000;95:1758-1766.
10. Mahon FX, Deininger M, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96:1070-1079.
11. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR-ABL-transformed hematopoietic cell lines. Blood 2000(Jun 1);95(11):3498-3505.
12. + leukemic cells to the Abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-1650.
13. + chronic myeloid leukemia during the first 13 weeks of therapy with STI571. Blood Cells Mol Dis 2002;28:75-85.
14. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
15. Kreuzer KA, Lass U, Nagel S et al. Applicability of an absolute quantitative procedure to monitor intra-individual BCR-ABL transcript kinetics in clinical samples of chronic myelogenous leukemia patients. Int J Cancer 2000;86:741-746.
16. Kreuzer KA, Lass U, Landt O, et al. A highly sensitive and specific fluorescence RT-PCR assay for the pseudogene free detection of β-actin transcripts as quantitative reference, Clin Chem 1999;45:297-300.
17. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-652.
18. Jørgensen HG, Elliott MA, Allan EK, Carr CE, Holyoake TL, Smith KD. α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 2002;99:713-715.